/
OABI
$2.57+$0.05 (+1.98%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$365.3M
145M shares
52-week range
$1.30 – $2.79
85% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
CS
Borrow rate
0.42%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$0.16
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $18.3M | $23.3M | $34.7M | $59.1M | $34.2M | $26.4M | $18.7M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $22.1M |
| Gross profit | $18.3M | $23.3M | $34.7M | $59.1M | $34.2M | $26.4M | −$3.4M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -18.2% |
| R&D | $13.2M | $24.8M | $39.2M | $48.4M | $56.5M | $55.1M | $47.8M |
| Operating income | −$13.0M | −$25.6M | −$35.6M | −$26.6M | −$69.4M | −$74.5M | −$71.5M |
| EBITDA | −$3.3M | −$10.9M | −$18.1M | −$7.8M | −$44.9M | −$47.8M | −$44.5M |
| Net income | −$13.6M | −$17.6M | −$27.0M | −$22.3M | −$50.6M | −$62.0M | −$64.8M |
| Net margin | -74.2% | -75.5% | -77.8% | -37.8% | -148.2% | -235.1% | -347.0% |
| EPS (diluted) | -0.12 | -0.15 | -0.24 | -0.26 | -0.51 | -0.61 | -0.57 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $31M | $-0.41 | $-0.42–$-0.40 | 4 |
| 2027 | $46M | $-0.27 | $-0.37–$-0.15 | 4 |
| 2028 | $65M | $-0.13 | $-0.28–$-0.05 | 4 |
| 2029 | $93M | $0.05 | $0.03–$0.07 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
OmniAb, Inc. Common Stock
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
www.omniab.com- Employees
- 89
- IPO / List date
- Nov 1, 2022
- HQ
- EMERYVILLE, CA
Held by traders on TradeandTell
No one on the platform currently holds OABI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 269,600 | $423.3K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OABI yet.
